Cognitive Dysfunction caused by Cerebral Small Vessel Disease
Conditions
Interventions
Experimental group:Naokang II granule
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Meeting the diagnostic criteria for CSVCI in both Traditional Chinese Medicine and Western Medicine; 2) Aged between 40 and 80 years; 3) Able to cooperate in completing neuropsychological tests; 4) Voluntarily participating in the trial and signing an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients already diagnosed with dementia; 2) Cognitive impairment caused by other diseases such as hypothyroidism, mental disorders, or traumatic brain injury; 3) History of other neurological diseases such as epilepsy or intracranial space-occupying lesions; 4) Allergy or contraindication to the drugs used in the study; 5) Comorbid organ dysfunction, such as liver cirrhosis or renal failure; 6) Comorbid severe infectious diseases; 7) History of drug dependence or alcoholism; 8) Inability to cooperate with cognitive function assessments; 9) Use of any cognitive-enhancing drugs within 30 days prior to the study, including vitamin supplements (e.g., vitamin E), multivitamins, donepezil hydrochloride, galantamine, rivastigmine, memantine hydrochloride, or any other recently approved drug therapies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment (MoCA) scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine syndrome scores;Mini-Mental State Examination (MMSE) scores;Activities of Daily Living (ADL) scale scores;total Cerebral Small Vessel Disease (CSVD) burden scores ; | — |
Countries
China
Contacts
Public ContactFeixue Wang
Xuanwu Hospital Capital Medical University
Outcome results
None listed